EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serendipitous and Systematic Chemoproteomic Discovery of MBLAC2, HINT1, and NME1-4 Inhibitors from Histone Deacetylase-Targeting Pharmacophores

Severin Lechner iD, Shuyao Sha, Jigar Paras Sethiya, Patrycja Szczupak, Rafal Dolot, Santosh Lomada, Amirhossein Sakhteman, Johanna Tushaus, Polina Prokofeva, Michael Krauss, Ferdinand Breu, Katharina Vögerl und 9 weitere

ACS Chemical Biology · 2025

DOI: 10.1021/acschembio.5c00108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2025. Verfasst von Severin Lechner und 20 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Proteomics and Bioanalytics, TUM School of Life Sciences, Technical University of Munich, Freising 85354, Germany. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Nerve Tissue Proteins, Histone Deacetylases. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium f?r Bildung und Forschung, Deutsche Forschungsgemeinschaft, EU Regional Operational Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metalloenzyme inhibitors often incorporate a hydroxamic acid moiety to bind the bivalent metal ion cofactor within the enzyme's active site. Recently, inhibitors of Zn2+-dependent histone deacetylases (HDACs), including clinically advanced drugs, have been identified as potent inhibitors of the metalloenzyme MBLAC2. However, selective chemical probes for MBLAC2, which are essential for studying its inhibitory effects, have not yet been reported. To discover highly selective MBLAC2 inhibitors, we conducted chemoproteomic target deconvolution and selectivity profiling of a library of hydroxamic acid-type molecules and other metal-chelating compounds. This screen revealed MBLAC2 as a frequent off-target of supposedly selective HDAC inhibitors, including the HDAC6 inhibitor SW-100. Profiling a focused library of SW-100-related phenylhydroxamic acids led to identifying two compounds, KV-65 and KV-79, which exhibit nanomolar binding affinity for MBLAC2 and over 60-fold selectivity compared to HDACs. Interestingly, some phenylhydroxamic acids were found to bind additional off-targets. We identified KV-30 as the first drug-like inhibitor of the histidine triad nucleotide-binding protein HINT1 and confirmed its mode of inhibition through a cocrystal structure analysis. Furthermore, we report the discovery of the first inhibitors for the undrugged nucleoside diphosphate kinases NME1, NME2, NME3, and NME4. Overall, this study maps the target and off-target landscape of 53 metalloenzyme inhibitors, providing the first selective MBLAC2 inhibitors. Additionally, the discovery of pharmacophores for NME1-4 and HINT1 establishes a foundation for the future design of potent and selective inhibitors for these targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsNerve Tissue ProteinsHistone DeacetylasesHumansDrug DiscoveryHydroxamic AcidsProteomics

Substanzen

Histone Deacetylase InhibitorsHINT1 protein, humanNerve Tissue ProteinsHistone DeacetylasesHydroxamic Acids

Autor:innen und Institutionen

  • Chair of Proteomics and Bioanalytics, TUM School of Life Sciences, Technical University of Munich, Freising 85354, Germany.
  • Department of Medicinal Chemistry, University of Minnesota College of Pharmacy, Minneapolis, Minnesota 55414, United States.
  • Division of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Łódź 90-363, Poland.
  • Experimental Pharmacology Mannheim, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Ludolf-Krehl-Str. 13-17, Mannheim 68167, Germany.
  • Department of Biology, Chemistry, Pharmacy, Leibniz Institute fur Molecular Pharmacologie, Robert-Roessle-Strasse 10, Berlin 13125, Germany.
  • Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University Munich, Munich 81377, Germany.

ORCID-Profile: Severin Lechner, Carston Wagner, Guillaume Médard, Bernhard Kuster

Förderung

  • Bundesministerium f?r Bildung und Forschung
  • Deutsche Forschungsgemeinschaft
  • EU Regional Operational Program

Zitieren

APA

Lechner, S., Sha, S., Sethiya, J. P., Szczupak, P., Dolot, R., Lomada, S., Sakhteman, A., Tushaus, J., Prokofeva, P., Krauss, M., Breu, F., Vögerl, K., Morgenstern, M., German Mouse Clinic Consortium, Hrabě de Angelis, M., Haucke, V., Wieland, T., Wagner, C., Médard, G., …, & Kuster, B. (2025). Serendipitous and Systematic Chemoproteomic Discovery of MBLAC2, HINT1, and NME1-4 Inhibitors from Histone Deacetylase-Targeting Pharmacophores. ACS Chemical Biology. https://doi.org/10.1021/acschembio.5c00108

Vancouver

Lechner S, Sha S, Sethiya JP, Szczupak P, Dolot R, Lomada S, et al. Serendipitous and Systematic Chemoproteomic Discovery of MBLAC2, HINT1, and NME1-4 Inhibitors from Histone Deacetylase-Targeting Pharmacophores. ACS Chemical Biology. 2025. doi:10.1021/acschembio.5c00108

BibTeX
@article{Lechner2025,
  author = {Lechner, Severin and Sha, Shuyao and Sethiya, Jigar Paras and Szczupak, Patrycja and Dolot, Rafal and Lomada, Santosh and Sakhteman, Amirhossein and Tushaus, Johanna and Prokofeva, Polina and Krauss, Michael and Breu, Ferdinand and Vögerl, Katharina and Morgenstern, Martin and German Mouse Clinic Consortium, German Mouse Clinic Consortium and Hrabě de Angelis, Martin and Haucke, Volker and Wieland, Thomas and Wagner, Carston and Médard, Guillaume and Bracher, Franz and Kuster, Bernhard},
  title = {Serendipitous and Systematic Chemoproteomic Discovery of MBLAC2, HINT1, and NME1-4 Inhibitors from Histone Deacetylase-Targeting Pharmacophores},
  journal = {ACS Chemical Biology},
  year = {2025},
  doi = {10.1021/acschembio.5c00108}
}
Kostenlos starten →